Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Mills

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Preventing Chronic Disease|October 9, 2015
Using Concept Mapping to Develop a Strategy for Self-Management Support for Underserved Populations Living With Chronic Conditions, British Columbia, August 2013-June 2014Susan L Mills, Kim Bergeron, Guillermina Pérez
Aviation, Space, and Environmental Medicine|June 12, 2002
Central effects of cinnarizine: restricted use in aircrewAnthony N Nicholson, Barbara M Stone, Claire Turner, et al.
Health Promotion International|June 1, 2016
Toward consensus on self-management support: the international chronic condition self-management support frameworkSusan L Mills, Teresa J Brady, Janaki Jayanthan, et al.
Health Promotion Practice|January 6, 2018
Intercountry Consensus Building: Lessons From Developing a Chronic-Conditions Self-Management Support FrameworkSusan L Mills, Shabnam Ziabakhsh, Teresa J Brady, et al.
BMJ Open|July 4, 2014
Understanding how self-management interventions work for disadvantaged populations living with chronic conditions: protocol for a realist synthesisSusan L Mills, Javiera Pumarino, Nancy Clark, et al.
Alzheimer'S Research & Therapy|October 18, 2013
Dominantly Inherited Alzheimer Network: facilitating research and clinical trialsKrista L Moulder, B Joy Snider, Susan L Mills, et al.
Journal of Pineal Research|October 25, 2011
The spectral composition of evening light and individual differences in the suppression of melatonin and delay of sleep in humansNayantara Santhi, Helen C Thorne, Daan R van der Veen, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Preventing Chronic Disease|October 9, 2015
Using Concept Mapping to Develop a Strategy for Self-Management Support for Underserved Populations Living With Chronic Conditions, British Columbia, August 2013-June 2014Susan L Mills, Kim Bergeron, Guillermina Pérez
Aviation, Space, and Environmental Medicine|June 12, 2002
Central effects of cinnarizine: restricted use in aircrewAnthony N Nicholson, Barbara M Stone, Claire Turner, et al.
Health Promotion International|June 1, 2016
Toward consensus on self-management support: the international chronic condition self-management support frameworkSusan L Mills, Teresa J Brady, Janaki Jayanthan, et al.
Health Promotion Practice|January 6, 2018
Intercountry Consensus Building: Lessons From Developing a Chronic-Conditions Self-Management Support FrameworkSusan L Mills, Shabnam Ziabakhsh, Teresa J Brady, et al.
BMJ Open|July 4, 2014
Understanding how self-management interventions work for disadvantaged populations living with chronic conditions: protocol for a realist synthesisSusan L Mills, Javiera Pumarino, Nancy Clark, et al.
Alzheimer'S Research & Therapy|October 18, 2013
Dominantly Inherited Alzheimer Network: facilitating research and clinical trialsKrista L Moulder, B Joy Snider, Susan L Mills, et al.
Journal of Pineal Research|October 25, 2011
The spectral composition of evening light and individual differences in the suppression of melatonin and delay of sleep in humansNayantara Santhi, Helen C Thorne, Daan R van der Veen, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 2